JP2018531987A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018531987A5 JP2018531987A5 JP2018529516A JP2018529516A JP2018531987A5 JP 2018531987 A5 JP2018531987 A5 JP 2018531987A5 JP 2018529516 A JP2018529516 A JP 2018529516A JP 2018529516 A JP2018529516 A JP 2018529516A JP 2018531987 A5 JP2018531987 A5 JP 2018531987A5
- Authority
- JP
- Japan
- Prior art keywords
- optionally substituted
- tautomer
- stereoisomer
- pharmaceutically acceptable
- acceptable salt
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims 23
- 125000000623 heterocyclic group Chemical group 0.000 claims 22
- 150000003839 salts Chemical class 0.000 claims 21
- 239000001257 hydrogen Substances 0.000 claims 18
- 229910052739 hydrogen Inorganic materials 0.000 claims 18
- 125000000547 substituted alkyl group Chemical group 0.000 claims 18
- 150000002431 hydrogen Chemical class 0.000 claims 17
- 125000001072 heteroaryl group Chemical group 0.000 claims 11
- 125000004452 carbocyclyl group Chemical group 0.000 claims 10
- 229910052736 halogen Inorganic materials 0.000 claims 9
- 150000002367 halogens Chemical class 0.000 claims 9
- 125000002252 acyl group Chemical group 0.000 claims 8
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims 8
- 239000008194 pharmaceutical composition Substances 0.000 claims 7
- 125000003107 substituted aryl group Chemical group 0.000 claims 7
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 4
- 125000002837 carbocyclic group Chemical group 0.000 claims 4
- 208000031671 Large B-Cell Diffuse Lymphoma Diseases 0.000 claims 3
- 206010028980 Neoplasm Diseases 0.000 claims 3
- 125000000217 alkyl group Chemical group 0.000 claims 3
- 201000011510 cancer Diseases 0.000 claims 3
- 206010012818 diffuse large B-cell lymphoma Diseases 0.000 claims 3
- 201000010099 disease Diseases 0.000 claims 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 3
- 230000002062 proliferating effect Effects 0.000 claims 3
- 108010016626 Dipeptides Proteins 0.000 claims 2
- 101150113681 MALT1 gene Proteins 0.000 claims 2
- 102000057613 Mucosa-Associated Lymphoid Tissue Lymphoma Translocation 1 Human genes 0.000 claims 2
- 108700026676 Mucosa-Associated Lymphoid Tissue Lymphoma Translocation 1 Proteins 0.000 claims 2
- 150000001413 amino acids Chemical class 0.000 claims 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims 2
- 239000012472 biological sample Substances 0.000 claims 2
- 229910052757 nitrogen Inorganic materials 0.000 claims 2
- 125000006239 protecting group Chemical group 0.000 claims 2
- 125000005017 substituted alkenyl group Chemical group 0.000 claims 2
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 claims 2
- 208000023275 Autoimmune disease Diseases 0.000 claims 1
- 102000046016 B-Cell CLL-Lymphoma 10 Human genes 0.000 claims 1
- 108700024832 B-Cell CLL-Lymphoma 10 Proteins 0.000 claims 1
- 208000036170 B-Cell Marginal Zone Lymphoma Diseases 0.000 claims 1
- 101150074953 BCL10 gene Proteins 0.000 claims 1
- 102000007443 Deubiquitinating Enzyme CYLD Human genes 0.000 claims 1
- 108010086291 Deubiquitinating Enzyme CYLD Proteins 0.000 claims 1
- 206010061850 Extranodal marginal zone B-cell lymphoma (MALT type) Diseases 0.000 claims 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 1
- 206010025323 Lymphomas Diseases 0.000 claims 1
- 201000003791 MALT lymphoma Diseases 0.000 claims 1
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims 1
- 150000001735 carboxylic acids Chemical class 0.000 claims 1
- 238000003776 cleavage reaction Methods 0.000 claims 1
- 230000008878 coupling Effects 0.000 claims 1
- 238000010168 coupling process Methods 0.000 claims 1
- 238000005859 coupling reaction Methods 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 208000032839 leukemia Diseases 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 230000007017 scission Effects 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021135770A JP2021193093A (ja) | 2015-08-28 | 2021-08-23 | Ｍａｌｔ１阻害剤およびその使用 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562211629P | 2015-08-28 | 2015-08-28 | |
| US62/211,629 | 2015-08-28 | ||
| US201562256672P | 2015-11-17 | 2015-11-17 | |
| US62/256,672 | 2015-11-17 | ||
| PCT/US2016/049038 WO2017040304A1 (en) | 2015-08-28 | 2016-08-26 | Malt1 inhibitors and uses thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021135770A Division JP2021193093A (ja) | 2015-08-28 | 2021-08-23 | Ｍａｌｔ１阻害剤およびその使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018531987A JP2018531987A (ja) | 2018-11-01 |
| JP2018531987A5 true JP2018531987A5 (OSRAM) | 2019-10-03 |
| JP6989505B2 JP6989505B2 (ja) | 2022-01-05 |
Family
ID=58188144
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018529516A Active JP6989505B2 (ja) | 2015-08-28 | 2016-08-26 | Ｍａｌｔ１阻害剤およびその使用 |
| JP2021135770A Pending JP2021193093A (ja) | 2015-08-28 | 2021-08-23 | Ｍａｌｔ１阻害剤およびその使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021135770A Pending JP2021193093A (ja) | 2015-08-28 | 2021-08-23 | Ｍａｌｔ１阻害剤およびその使用 |
Country Status (4)
| Country | Link |
|---|---|
| US (1) | US10711036B2 (OSRAM) |
| EP (1) | EP3341007B1 (OSRAM) |
| JP (2) | JP6989505B2 (OSRAM) |
| WO (1) | WO2017040304A1 (OSRAM) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PE20190656A1 (es) | 2016-07-29 | 2019-05-08 | Lupin Ltd | Compuestos de tiazolo-piridina sustituida como inhibidores de malt1 |
| MA45787A (fr) | 2016-07-29 | 2019-06-05 | Lupin Ltd | Composés de thiazolo-pyridine substitués en tant qu'inhibiteurs de malt1 |
| EP3495348A4 (en) * | 2016-07-29 | 2020-01-22 | Toray Industries, Inc. | GUANIDINE DERIVATIVE AND ITS USE FOR MEDICAL PURPOSES |
| BR112020013285A2 (pt) * | 2017-12-28 | 2020-12-01 | The General Hospital Corporation | direcionamento do complexo de sinalossoma cbm que induz células t reguladoras a atingirem o microambiente tumoral |
| WO2019159097A1 (en) * | 2018-02-14 | 2019-08-22 | Sun Pharmaceutical Industries Limited | Crystalline polymorphic forms of acalabrutinib |
| JP7296407B2 (ja) * | 2018-06-18 | 2023-06-22 | ヤンセン ファーマシューティカ エヌ．ベー． | Ｍａｌｔ１阻害剤としてのピラゾール誘導体 |
| JP7296408B2 (ja) * | 2018-06-18 | 2023-06-22 | ヤンセン ファーマシューティカ エヌ．ベー． | Ｍａｌｔ１阻害剤としてのピラゾール誘導体 |
| US12403121B2 (en) * | 2018-10-09 | 2025-09-02 | The Research Institute At Nationwide Children's Hospital | Anticancer rocaglamide derivatives |
| CN111358959B (zh) * | 2019-10-10 | 2021-03-26 | 鹿文葆 | Roquin1蛋白及其编码基因在制备抑制肿瘤的药物中的应用 |
| CN111686111B (zh) * | 2020-06-09 | 2023-06-13 | 南方医科大学 | Malt1蛋白酶抑制剂在制备非小细胞肺癌治疗药物中的应用 |
| AU2021361057A1 (en) * | 2020-10-16 | 2023-06-08 | Rarefied Biosciences, Inc. | Malt1 modulators and uses thereof |
| CN113057957A (zh) * | 2021-03-30 | 2021-07-02 | 福建中医药大学 | 葛杜宁及其衍生物在制备抗氧化药物和/或化妆品及治疗类风湿性关节炎药物中的用途 |
| CN113024565B (zh) * | 2021-03-31 | 2022-09-13 | 上海启甄环境科技有限公司 | 一种放射性同位素碳-14标记依鲁替尼及其合成方法 |
| US20250115636A1 (en) * | 2022-02-03 | 2025-04-10 | Purdue Research Foundation | Peptidomimetic inhibitors of protein n-terminal methyltransferase 1, composition, and method of use |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5210272A (en) | 1990-02-16 | 1993-05-11 | Prototek, Inc. | Process for forming a fluoromethyl ketone |
| AU733562B2 (en) | 1996-06-18 | 2001-05-17 | Warner-Lambert Company | Process for the preparation of chiral keto-heterocycles of basic amino acids |
| CA2378291A1 (en) | 1999-07-07 | 2001-01-18 | Astrazeneca Uk Limited | Quinazoline derivatives |
| WO2009060835A1 (ja) | 2007-11-05 | 2009-05-14 | Kyoto University | 新規ユビキリン結合性小分子 |
| WO2012071414A2 (en) | 2010-11-22 | 2012-05-31 | Board Of Regents Of The University Of Nebraska | Quinoxaline compounds and uses thereof |
| AU2013342267B2 (en) * | 2012-11-09 | 2017-01-12 | Cornell University | Small molecule inhibitors of MALT1 |
| KR20250127179A (ko) | 2014-04-14 | 2025-08-26 | 아비나스 오퍼레이션스, 인코포레이티드 | 단백질분해의 이미드-기초된 조절인자 및 연관된 이용 방법 |
| RS59039B1 (sr) | 2014-05-28 | 2019-08-30 | Novartis Ag | Novi derivati pirazolo pirimidina i njihova primena kao inhibitora malt1 |
| WO2018085247A1 (en) | 2016-11-01 | 2018-05-11 | Cornell University | Compounds for malt1 degradation |
-
2016
- 2016-08-26 EP EP16842694.8A patent/EP3341007B1/en active Active
- 2016-08-26 WO PCT/US2016/049038 patent/WO2017040304A1/en not_active Ceased
- 2016-08-26 US US15/755,951 patent/US10711036B2/en active Active
- 2016-08-26 JP JP2018529516A patent/JP6989505B2/ja active Active
-
2021
- 2021-08-23 JP JP2021135770A patent/JP2021193093A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018531987A5 (OSRAM) | ||
| JP7745892B2 (ja) | Ｎ４－ヒドロキシシチジンおよび誘導体ならびにそれらに関連する抗ウイルス用途 | |
| KR102566924B1 (ko) | 케모카인 수용체 조절제 및 이의 용도 | |
| FI4073065T3 (fi) | Uusia metyylikinatsolinonijohdannaisia | |
| CY1119880T1 (el) | Παραγωγα πυρρολοπυριμιδινης για χρηση στη θεραπεια ιικων λοιμωξεων | |
| CN111372592A (zh) | N4-羟基胞苷及衍生物和与其相关的抗病毒用途 | |
| US20220193242A1 (en) | Immunophilin-dependent inhibitors and uses thereof | |
| JP2002540156A (ja) | 抗ウイルス治療用チアジアゾリルウレアまたはチオウレア誘導体 | |
| AU2018360855A1 (en) | Modulators of the integrated stress pathway | |
| JP2016508150A (ja) | ウイルス感染症を処置するための治療用化合物 | |
| JP2014503567A5 (OSRAM) | ||
| JP2009536620A5 (OSRAM) | ||
| JP2011219498A5 (OSRAM) | ||
| EP4327877A3 (en) | Dual atm and dna-pk inhibitors for use in anti-tumor therapy | |
| JP2015500885A5 (OSRAM) | ||
| JP2016540803A5 (OSRAM) | ||
| RU2007130144A (ru) | Гетероциклические соединения в качестве антагонистов cccr2b | |
| KR20230075524A (ko) | N-[5-(아미노술포닐)-4-메틸-1,3-티아졸-2-일]-n-메틸-2-[4-(2-피리디닐)-페닐]-아세트아미드 유리 염기 반수화물, 그의 제조 방법 및 용도 | |
| JP2019519512A5 (OSRAM) | ||
| JP2005526024A5 (OSRAM) | ||
| AU2020221247B2 (en) | Formulations comprising heterocyclic protein kinase inhibitors | |
| JP2017532316A5 (OSRAM) | ||
| JP2015522592A5 (OSRAM) | ||
| JP2018534316A5 (OSRAM) | ||
| US9676727B2 (en) | Myxovirus therapeutics, compounds, and uses related thereto |